A perfect score was attained! The Suzhou SpaceSeq tumor cell-free DNA EGFR test successfully passed the National Center

Achieved a perfect score in the assessment

Recently, the National Center for Clinical Laboratories (NCCL) released the results of the 2026 cell - free tumor DNA EGFR gene mutation detection project. Suzhou SpaceSeq MedLab of SpaceGen (hereinafter referred to as “Suzhou SpaceSeq”) once again achieved a perfect score in this assessment!

Project Results : External Quality Assessment

External Quality Assessment is an essential element of the internationally recognized total quality management framework for clinical laboratories. It is also a significant part of the quality management system in medical institutions and serves as a fundamental requirement for clinical laboratory management and laboratory accreditation in most countries worldwide.

The primary functions of External Quality Assessment include evaluating the proficiency of laboratories in performing specific tests and maintaining the testing capabilities of testing laboratories. It also involves identifying quality - related issues within laboratories, promoting the implementation of improvement measures, and enhancing the overall level of testing quality. Moreover, it is employed to assess the effectiveness and comparability of different testing methods, identify inter - laboratory variations, and enhance the confidence of doctors, patients, and other stakeholders in test results.

EGFR Mutant Gene

EGFR is one of the prevalent tumor driver genes and exists in a variety of solid tumors, particularly lung cancer. Lung cancer is the most common malignant tumor globally, and its mortality rate ranks first among malignant tumors. Approximately 85% of lung cancers are non - small cell lung cancer (NSCLC).

Among all NSCLC cases, EGFR is the most frequently mutated gene, with an incidence of about 40% to 50% in the Asian population. Conducting EGFR testing holds significant clinical implications for the diagnosis, typing, targeted therapy, and prognosis prediction of lung cancer.

Perseverance Leads to a Promising Future

Suzhou SpaceSeq has consistently regarded quality management as a crucial aspect of laboratory construction. It has established a comprehensive whole - process quality control system. From sample collection, experimental operation to data analysis and report generation, each link strictly adheres to various quality control measures to ensure the accuracy and reliability of test results. Achieving a full score in this External Quality Assessment (EQA) once again powerfully demonstrates the excellent testing capabilities of Suzhou SpaceSeq, a medical testing laboratory under SpaceGen. It can provide accurate and reliable test results for clinical patients, highlighting its leading position in the rigor of experimental operations and the standardization of management.

In the future, Suzhou SpaceSeq will, as always, pursue excellence, exercise strict control, offer reliable clinical testing services, and contribute to the development of precision tumor diagnosis and treatment.